Digital health formulary wars heat up. $40M price tag for a digital drug.

Issue 007. Digital health formulary wars heat up. $40M price tag for a digital drug.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a likely-not-to-be-repeated 89 percent open rate. Here's what's happening this week:

Your editor is preparing to take his 3-year-old and 5-year-old camping for the first time this weekend. Hit reply to talk me out of it (or to send more marshmallows).
Dexcom CEO Kevin Sayer told Jim Cramer in the next 12 months the company will launch the G6 version of its CGM that sends data direct-to-Apple Watch (bypassing the iPhone).
Benjamin D'hont of Alcimed has a helpful overview of the current state of digital therapeutics here.
Elsewhere, I've heard some curmudgeons throwing cold water on digital health companies that call themselves "digital therapeutics" if they use either CBT or real live

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Digital health formulary wars heat up. $40M price tag for a digital drug.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.